Rationale and design of the Helping Ease Renal failure with Bupi Yishen compared with the Angiotensin II Antagonist Losartan (HERBAAL) trial: a randomized controlled trial in non-diabetes stage 4 chronic kidney disease

BACKGROUND: Chronic kidney disease (CKD) is a global public health problem. Currently, as for advanced CKD populations, medication options limited in angiotensin-converting enzyme inhibitors (ACEi) and angiotensin receptor blockers (ARB), which were partially effective. A Chinese herbal compound, Bu...

Descripción completa

Detalles Bibliográficos
Autores principales: Mao, Wei, Zhang, Lei, Zou, Chuan, Li, Chuang, Wu, Yifan, Su, Guobin, Guo, Xinfeng, Wu, Yuchi, Lu, Fuhua, Lin, Qizhan, Wang, Lixin, Bao, Kun, Xu, Peng, Zhao, Daixin, Peng, Yu, Liang, Hui, Lu, Zhaoyu, Gao, Yanxiang, Jie, Xina, Zhang, La, Wen, Zehuai, Liu, Xusheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562196/
https://www.ncbi.nlm.nih.gov/pubmed/26351087
http://dx.doi.org/10.1186/s12906-015-0830-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4562196/
https://www.ncbi.nlm.nih.gov/pubmed/26351087
http://dx.doi.org/10.1186/s12906-015-0830-1

Ejemplares similares